Author
Corona Remedies IPO closes on December 10, 2025. The IPO comprises an entirely Offer for Sale (OFS) of ₹655.37 crore, with no fresh issue component. The price band for the issue is fixed at ₹1,008–₹1,062 per share.
The basis of allotment is expected to be finalized on December 11, 2025, while refunds and demat credit are scheduled for December 12, 2025. The shares are tentatively set to list on December 15, 2025 on both BSE and NSE.
Corona Remedies Ltd is a branded pharmaceutical formulations company focused on the Indian market, with a presence across multiple chronic and acute therapeutic segments.
Registrar: Bigshare Services Pvt. Ltd.
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 293.8× |
| HNIs | 28.30× |
| Retail Individual Investors (RII) | 30.29× |
| Employees | 15.56× |
| Total | 144.49× |
Corona Remedies Ltd is a branded pharmaceutical company operating in the Indian pharmaceutical market, with a portfolio spanning women’s healthcare, cardio-diabeto, pain management, urology, anti-infectives, nutraceuticals, orthopedics, and pediatrics.
In FY25, the company reported revenues of approximately ₹1,200 crore, while net profit rose sharply to around ₹149 crore, reflecting strong earnings growth and margin expansion.
Related
Recent
Adani Ports Q3 FY26 results: Volumes, logistics, and performance overview
NSE IPO: What We Know So Far About India’s Most Anticipated Listing
India–US Trade Deal 2026: A New Chapter in Global Commerce
The STT Change Explained: Why a Small Charge Ends Up Costing Traders Much More
Why Indian Defence Stocks are Falling After Budget 2026 — Despite Higher Spending